13 Active Studies

Huntingtons Disease Clinical Trials Near You

Find 13 actively recruiting huntingtons disease research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

13
Active Trials
53+
Locations
2,670
Participants Needed

Recruiting Studies

RecruitingNCT03781752

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes an...

4 locations(Gainesville, New York, Cincinnati)
500 participants
Icahn School of Medicine at Mount Sinai
View Study Details
RecruitingNCT05916339

AWARE: Management of ADHD in Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents wit...

10 locations(Irvine, Los Angeles, Portland)
500 participants
Daniel Coury
View Study Details
RecruitingNCT06973577

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety...

10 locations(Dothan, Little Rock, Rogers)
308 participants
Otsuka Pharmaceutical Development & Commercialization, Inc.
View Study Details
RecruitingNCT04781140

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD....

10 locations(Saraland, Fayetteville, Little Rock)
286 participants
Supernus Pharmaceuticals, Inc.
View Study Details
RecruitingNCT04421248

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high leve...

2 locations(Baltimore, Cincinnati)
214 participants
Donald Gilbert, MD, MS, FAAN, FAAP
View Study Details
RecruitingNCT06431256

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD

This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD....

10 locations(Dothan, Anaheim, Jacksonville)
168 participants
Ironshore Pharmaceuticals and Development, Inc
View Study Details
RecruitingNCT06215144

Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD...

10 locations(Anaheim, Lakeland, Maitland)
160 participants
Neurocentria, Inc.
View Study Details
RecruitingNCT05995535

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pre...

2 locations(Baltimore, Philadelphia)
150 participants
University of Pennsylvania
View Study Details
RecruitingNCT04373057

Prebiotic Galacto-oligosaccharide and Acute GVHD

The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help ...

2 locations(Kansas City, Durham)
128 participants
Duke University
View Study Details
RecruitingNCT04219280

Evaluating Treatment of ADHD in Children with Down Syndrome

Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates ...

4 locations(Sacramento, Boston, Cincinnati)
100 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNCT06673368

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD....

5 locations(Maitland, Decatur, Savannah)
60 participants
Neurocentria, Inc.
View Study Details
RecruitingNCT06826612

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease....

3 locations(Boston, Cincinnati, Columbus)
53 participants
Spark Therapeutics, Inc.
View Study Details
RecruitingNCT04120493

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) st...

10 locations(Birmingham, Tucson, San Francisco)
43 participants
UniQure Biopharma B.V.
View Study Details

Top Cities for Huntingtons Disease Clinical Trials

Huntingtons Disease clinical trials are recruiting across 53 cities. Here are the cities with the most active studies:

About Huntingtons Disease

Huntington's disease is an inherited condition that causes progressive degeneration of nerve cells in the brain, affecting movement, cognition, and behavior. It is caused by a mutation in the HTT gene. Current treatments manage symptoms, while gene-silencing therapies are being studied.

Clinical trials are advancing new treatments for huntingtons disease. Currently, 13 studies are recruiting a combined 2,670 participants across the United States. Research is being conducted by 12 organizations including Icahn School of Medicine at Mount Sinai, Daniel Coury, Otsuka Pharmaceutical Development & Commercialization, Inc. and 9 others.

2026 Huntingtons Disease Research Landscape

As of March 2026, the huntingtons disease clinical trial landscape includes 13 actively recruiting studies across 53 cities in the United States. These studies are collectively seeking 2,670 participants, with an average enrollment target of 205 per study.

Research is being led by 12 different organizations, including Icahn School of Medicine at Mount Sinai, Daniel Coury, Otsuka Pharmaceutical Development & Commercialization, Inc., Supernus Pharmaceuticals, Inc., Donald Gilbert, MD, MS, FAAN, FAAP, and 7 others. The large number of sponsors reflects significant research interest and investment in huntingtons disease treatment advancement.

Geographically, huntingtons disease trials are most concentrated in Boston, Massachusetts (6 trials); Cincinnati, Ohio (5 trials); Gainesville, Florida (3 trials); Columbus, Ohio (3 trials); Long Beach, California (3 trials) and 7 other cities.

Featured Huntingtons Disease Studies

Highlighted recruiting studies for huntingtons disease, selected by enrollment size and research scope.

RecruitingNCT03781752

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.

Sponsor: Icahn School of Medicine at Mount Sinai· 500 participants· 4 locations (Gainesville, New York, Cincinnati, Seattle)
View full study details →
RecruitingNCT05916339

AWARE: Management of ADHD in Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD med...

Sponsor: Daniel Coury· 500 participants· 10 locations (Irvine, Los Angeles, Portland, Boston)
View full study details →
RecruitingNCT06973577

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.· 308 participants· 10 locations (Dothan, Little Rock, Rogers, Encino)
View full study details →

Frequently Asked Questions About Huntingtons Disease Clinical Trials

Are there huntingtons disease clinical trials near me?

Yes, there are 13 huntingtons disease clinical trials currently recruiting across 53+ cities in the United States, including Boston, Massachusetts; Cincinnati, Ohio; Gainesville, Florida. Browse the studies above to find one at a location convenient for you.

How do I join a huntingtons disease clinical trial?

To join a huntingtons disease clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are huntingtons disease clinical trials free?

Yes, participation in huntingtons disease clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of huntingtons disease treatments are being studied?

Current huntingtons disease clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 12 research organizations.

Is it safe to participate in huntingtons disease clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 1, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov